AUPH logo

AURINIA PHARMACEUTICALS INC

AUPHNASDAQ
πŸ† #1835 by market capUS Equity
β€”β€”
Quote unavailable
πŸ””
Track AUPH
Get earnings, price moves & breaking news on Telegram
Track
24hβ€”
7dβ€”
14dβ€”
30dβ€”
ytdβ€”
1yβ€”
🏦Market Cap
$1.97B
Small Cap
πŸ“ˆRevenue Growth (YoY)
21.0%
Healthy
πŸ“ŠGross Margin
90.6%
High
πŸ’΅FCF Margin
55.0%
Strong
βš–οΈP/S Ratio
6.1x
Fair
Otter Score
76
Strong
No chart data available for AUPH.

Trading Snapshot

Day Range
β€”
52-Week Range
$13.52 – $19.25
Volume (shares)
β€”
Avg Volume (shares)
β€”
Shares Outstanding
134.0M
Next Earnings
β€”

Fundamentals Snapshot

Annual Revenue
$283M
Last Q Revenue
$84M
P/E Ratio
6.3
P/S Ratio
6.1x
EPS (TTM)
$2.29
Dividend Yield
β€”
Dilution (1yr)
βˆ’6.1%
AUPH logo

AURINIA PHARMACEUTICALS INC

AUPH
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$283Mβ–² +20.4% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
88.5%β–² +0.5% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
$105Mβ–Ό βˆ’2338.4% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
$135Mβ–² +207.0% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
138.7Mβ–Ό βˆ’6.1% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$5Mβ–² +$1M YoY
StockOtter Β· stockotter.space

About AURINIA PHARMACEUTICALS INC

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5β˜… and equally weighted (20%), averaged to a 0–100 score:πŸ’Ž Quality β€” gross marginπŸš€ Growth β€” revenue YoYβš–οΈ Valuation β€” P/S ratio⚑ Momentum β€” 30-day price changeπŸ’§ Dilution β€” 1-yr share issuance (buybacks score higher)
πŸ’ŽQualityβ˜…β˜…β˜…β˜…β˜…
πŸš€Growthβ˜…β˜…β˜…β˜…β˜…
βš–οΈValuationβ˜…β˜…β˜…β˜…β˜…
⚑Momentumβ˜…β˜…β˜…β˜…β˜…
πŸ’§Dilutionβ˜…β˜…β˜…β˜…β˜…
Overall Score
Strong
76/100
Analyst data unavailable.

Latest News & Updates

News unavailable.